Risks and management of side effects of targeted therapies

被引：0
|
作者：
Gutzmer, R. [1 ]
Strumberg, D. [2 ]
机构：
[1] Hannover Med Sch, Hauttumorzentrum Hannover HTZH, Klin Dermatol Allergol & Venerol, Hannover, Germany
[2] Klin Ruhr Univ Bochum, Marienhosp Herne, Med Klin 3, Herne, Germany
来源：
ONKOLOGE | 2013年 / 19卷 / 10期
关键词：
Targeted therapies; Immunotherapy; Side effects; Molecular signalling pathways; Multikinase inhibitors; TYROSINE KINASE INHIBITORS; INDUCED DIARRHEA; CARDIOTOXICITY; MECHANISMS; HYPERTENSION;
D O I：
10.1007/s00761-013-2500-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Targeted therapies are increasingly being used in the medicinal therapy of tumors. The targeted manipulation of molecular signalling pathways or immune reactions can result in adverse effects which are in part novel and require special attention. Research and analysis of the literature. This article reviews the side effects of multikinase inhibitors, MAP kinase inhibitors (in particular EGFR, KIT and BRAF inhibitors) and CTLA-4 inhibitors and discusses the management. The knowledge of these side effects must be thoroughly inccorporated in the clinical examination and the treating physician should have a comprehensive knowledge of them.
引用
收藏
页码：863 / 869
页数：7
相关论文
共 50 条
  • [1] Paronychia - side effects of targeted therapies and their management
    Dickson, J.
    Munson, J.
    LUNG CANCER, 2015, 87 : S35 - S35
  • [2] Nursing management on side effects in the new targeted therapies
    San Francisco, J.
    Munoz, M. Martinez
    EJC SUPPLEMENTS, 2007, 5 (04): : 422 - 422
  • [3] Management of side effects of targeted therapies in renal cancer: cutaneous side effects
    Robert, Caroline
    Gimel, Pierre
    BULLETIN DU CANCER, 2011, 98 : S35 - S46
  • [4] Management of side effects of targeted therapies in renal cancer: iatrogenic side effects
    Massard, Christophe
    Patard, Jean-Jacques
    Hermine, Olivier
    Ravaud, Alain
    BULLETIN DU CANCER, 2011, 98 : S79 - S94
  • [5] Management of side effects of targeted therapies in renal cancer: pulmonary side effects
    Girard, Philippe
    Bergeron, Anne
    Soulie, Michel
    BULLETIN DU CANCER, 2011, 98 : S95 - S115
  • [6] Management of side effects of targeted therapies in renal cancer: nephrological side effects
    Izzedine, Hassan
    Negrier, Sylvie
    Neuzillet, Yann
    Zini, Laurent
    BULLETIN DU CANCER, 2011, 98 : S7 - S18
  • [7] Side Effects of Targeted Therapies
    Fathallah, N.
    Ladhari, C.
    Ouni, B.
    Larif, S.
    Baccouche, K.
    Slim, R.
    Ben Salem, C.
    DRUG SAFETY, 2018, 41 (11) : 1189 - 1190
  • [8] Molecular Targeted Therapies for Solid Tumors: Management of Side Effects
    Gruenwald, Viktor
    Soltau, Jens
    Ivanyi, Philipp
    Rentschler, Jochen
    Reuter, Christoph
    Drevs, Joachim
    ONKOLOGIE, 2009, 32 (03): : 129 - 138
  • [9] Management of side effects of targeted therapies in renal cancer: stomatological side effects (mucositis, epistaxis)
    Agbo-Godeau, Scarlette
    Nicolas-Virelizier, Emmanuelle
    Scotte, Florian
    BULLETIN DU CANCER, 2011, 98 : S117 - S126
  • [10] Management of side-effects of targeted therapies in renal cancer: gastrointestinal side-effects
    Davin, Jean-Louis
    Ducrotte, Philippe
    Houede, Nadine
    BULLETIN DU CANCER, 2011, 98 : S69 - S78
12345